Compare Neurocrine Biosciences Inc (NBIX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs United Parcel Service Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while United Parcel Service Inc trades at $99.68 (market cap $84.41B). The key difference: United Parcel Service Inc is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and United Parcel Service Inc pays a 6.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | UPS | |
|---|---|---|
Market Cap | $15.77B | $84.41B |
Sector | Health | Industrials |
52-Week High | $185.50 | $120.00 |
52-Week Low | $123.10 | $82.58 |
Enterprise Value | $15.78B | $108.43B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
UPS stock trades at $100.48, down 1.78% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. The company announced a $2B+ global investment to enhance logistics and appointed a new Chief Global Operations Officer, signaling strategic shifts. Valuation metrics include a P/E of 18.68 and P/S of 0.95, with a dividend yield of 6.2% based on the $1.64 per share payout.
The outlook is mixed: analyst consensus leans neutral with a $117.90 price target, but risks include declining net income margins and high dividend payout ratios limiting investment flexibility. Upside potential exists from efficiency gains and global expansion, while macroeconomic pressures and competitive threats pose challenges for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
